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Abstract: Cholesteryl ester transfer protein (CETP) plays a key role in lipid metabolism. Thus, variations in the CETP 
gene may be clinically relevant.  
Newly started atorvastatin users (n=212) were genotyped for CETP genetic variants (TaqIB and I405V). Homozygotes  
for B1 allele of TaqIB polymorphism had lower plasma high density lipoprotein cholesterol (HDL-C) compared with 
B1B2 or B2B2 genotypes (p=0.03, for each). Homozygotes for I allele of I405V polymorphism had lower plasma HDL-C 
compared with IV or VV genotypes (p=0.001, for each). In the whole population, the B1 carriers increased HDL-C levels 
by 4% after atorvastatin treatment, compared with B2 carriers, where a 4% decrease occurred (p=0.03). Also homozy-
gotes for B1 allele decreased triglyceride levels to a lesser, though not significant, degree compared to B1B2 or B2B2 
genotypes.  
CETP TaqIB or I405V polymorphisms seem to modify the lipid lowering response to atorvastatin treatment. This   
knowledge may help design more effective hypolipidaemic treatment. 
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INTRODUCTION 
  Cholesteryl ester transfer protein (CETP) plays a major 
role in modifying lipoprotein particles by mediating the 
transfer of cholesteryl esters from high-density lipoprotein 
(HDL) particles to apolipoprotein B-containing lipoproteins 
in exchange for triglycerides (TG) [1]. The CETP gene en-
compasses 16 exons, on chromosome 16q12-16q21; several 
CETP polymorphisms have been identified including I405V 
and TaqIB which are associated
  with reduced CETP mass 
and increased HDL cholesterol (HDL-C) [2]. I405V results 
in a single amino acid change at codon 405 in exon 14; in 
several studies, the I405V allele was associated with lower 
CETP levels [2]. TaqIB has been shown to be a silent base 
change affecting the 277th nucleotide in the first intron of 
the gene [3]. The B2 allele (absence of the TaqI restriction 
site) at this polymorphic site has been associated in normoli-
pemic subjects with increased HDL-C levels and decreased 
CETP activity and levels [4].  
  HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) 
reductase inhibitors (statins) are the main drugs used to 
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reduce plasma low density lipoprotein cholesterol (LDL-C) 
levels. Also, statins can be administrated to subjects with 
high triglyceride (TG) and low HDL-C levels (a dyslipidae-
mic combination which often coexists) [5, 6]. There is con-
siderable variation in the response to statin treatment [7]. 
Although most subjects derive a 30% to
 50% reduction in 
LDL-C cholesterol with statin therapy, there is wide varia-
tion in the dose response. Environmental and genetic factors 
may contribute to this variability. In line with our previous 
work [8], we assessed whether 2 common polymorphisms of 
CETP (I405V and TaqIB) influence the lipid response after 
treatment with atorvastatin.  
SUBJECTS AND METHODS 
Subjects 
 Ad  hoc power analysis showed that in order to detect 
two-sided differences higher than 20% in one of the main 
outcome variables (TG) before and after treatment with 
atorvastatin, achieving statistical power equal to 90% at a 
significance level less than 0.05, we had to recruit at least 
190 individuals for each group. Due to unexpected condi-
tions, more people entered the study, potentially increasing 
its statistical power. We genotyped 212 Greek unrelated hy-
percholesterolaemic subjects (141 men and 71 women) aged 298    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Kolovou et al. 
56.8 (±12.9) years with primary hypercholesterolemia. Addi-
tional inclusion criteria included a stable medication (pa-
tients with coronary artery disease were on cardioselective -
blockers and aspirin, patients with hypertension were on 
angiotensin converting enzyme inhibitors) regimen and diet 
for at least 4 weeks prior to study screening. Subjects with a 
history of stroke, renal diseases, and diabetes mellitus were 
excluded from the study. The subjects were assigned to 
atorvastatin treatment for at least 6 months. The dose of 
atorvastatin (10-40 mg/day) was adjusted according to the 
National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III) treatment goal for LDL-C based 
on risk category (LDL-C <130 mg/dl, < 100 mg/dl or < 70 
mg/dl; < 3.4 mmol/l, < 2.6 mmol/l or < 1.8 mmol/l) [9].  
  Subjects were further divided according to their baseline 
HDL-C levels into groups: 1. Low HDL group [HDL-C <40 
mg/dl (<1 mmol/l)] and 2. High HDL group [HDL 40 
mg/dl (1 mmol/l)]. All subjects were started on atorvastatin 
as the only lipid lowering drug. Exclusion criteria were 
heavy drinking as well as liver and renal disease. Our Institu-
tional Review Board approved the study. 
DNA Analysis and Determination of Blood Lipids and 
Glucose 
  The CETP (TaqIB, I405V) polymorphisms were detected 
by using Polymerase Chain Reaction and Restricted Frag-
ment Length Polymorphism analysis as previously described 
[10,11]. The measurement of total, LDL-C, HDL-C and TG 
was performed as described elsewhere [10]. Briefly, total 
cholesterol, TG and HDL-C levels were measured using en-
zymatic colorimetric methods, on a Roche Integra Bio-
chemical analyzer, with commercially available kits (Roche 
Diagnostics Gmbh, Hannheim, Germany). The serum LDL-
C levels were calculated using the Friedewald formula in 
subjects with TG levels < 400 mg/dl.  
Statistical Analysis 
  All continuous variables are shown as median and inter-
quartile range (25
th, 75
th percentile) since they all (except for 
age and BMI) deviated from normality. However, for facili-
tation reasons, age and BMI are also treated as non-normally 
distributed variables. All categorical variables are presented 
as relative (percentage) frequencies. The Kruskal-Wallis H 
statistic was used to compare the continuous variables 
among the 3 genotype groups, while the Mann-Whitney U 
test was used to compare the continuous variables between 
the 2 groups of carriers. Wilcoxon signed-rank test was used 
to evaluate the differences before and after treatment. The 
Pearson’s chi-square test was used to evaluate any associa-
tion between categorical variables and genotypes/alleles. The 
differences in total cholesterol, TGs, HDL-C and LDL-C 
before and after atorvastatin treatment were also described as 
% difference, based on the following rule: % difference = 
[(variable after-variable before)/variable before]*100. All 
tests were 2-sided at a significance level of p <0.05. Data 
were analyzed using STATA™ (Version 9.0, Stata Corpora-
tion, College Station, TX 77845, USA).  
Results 
Genotype and Allele Frequencies in the Whole Cohort 
  The genotype frequency of the TaqIB and I405V poly-
morphisms was B1B1 31.9%, B1B2 54.3%, B2B2 13.8% 
and II 45.0%, IV 40.8%, VV 14.2%, respectively. The B1 
and B2 alleles were found at frequencies of 58.9% and 
41.1%, respectively, while the I and V alleles were found at 
65.5% and 34.5%, respectively. 
Baseline Lipid Profile According to Genotype in the Whole 
Cohort 
TaqIB Polymorphism 
  Homozygotes for B1 allele had lower plasma HDL-C 
compared with B1B2 and B2B2 genotype (p=0.03, for each, 
Table  1). Accordingly, the B2 allele was associated with 
higher HDL-C levels compared with B1 allele (p=0.02,   
Table 2). Total cholesterol, LDL-C and TG levels did not 
vary significantly among TaqIB genotypes (Table 1).  
I405V Polymorphism 
  The IV genotype was associated to higher HDL-C levels 
compared with II genotype (p=0.001). The V allele was as-
sociated woth higher HDL-C levels compared with I allele 
(p=0.04) (Table 2).  
Table 1.  Baseline Lipid Profile of the Study Cohort Based on TaqIB or I405V Genotypes 
CETP TaqIB  CETP I405V 
   B1B1 (n=67)  B1B2 (n=114)  B2B2 (n=29)  p  II (n=95)  IV (n=86)  VV (n=30)  p 
Age  (years)  59(21) 59(18) 54(23)  0.51  56(21)  59(19) 61(18)  0.25 
BMI  (kg/m2)  26(3) 27(5) 26(4)  0.57  27(4)  26(5) 27(4)  0,48 
TC  (mg/dl) 271(68) 294(66) 285(94)  0.06  280(69)  294(60) 272(75)  0.09 
TG  (mg/dl) 175(101) 144(122)  153(179)  0.46  167(123)  144(139) 147(99)  0.29 
HDL-C  (mg/dl)  40(15) 45(19) 49(24)  0.04  41(17)  48(21) 45(18)  0.004 
LDL-C  (mg/dl)  188(49) 195(88) 205(81)  0.62  185(81)  190(67) 194(88)  0.52 
Continuous variables are shown as median and interquartile range. Kruskal-Wallis H statistic was used to compare the continuous variables among the three genotype groups. CETP: 
cholesteryl ester transfer protein, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total cholesterol, TG: 
triglycerides. 
For TC, HDL and LDL, to convert from mg/dl to mmol/l divide by 38.8. For TG, to convert from mg/dl to mmol/l divide by 88.6 Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid  The Open Cardiovascular Medicine Journal, 2010, Volume 4    299 
  Baseline lipid profile according to genotype in Low HDL 
group and High HDL group.  
TaqIB Polymorphism 
  The B1 allele was more frequent in Low HDL group than 
in High HDL group (64.1% vs 53.4%, p=0.05), while the B2 
allele frequency was higher in High HDL group compared 
with Low HDL group (46.6% vs 35.9%, p=0.05).  
  In Low HDL group, B1B2 subjects or B2 allele carriers 
had higher total cholesterol than B1B1 subjects (p=0.03) or 
B1 allele carriers (p=0.01).  
  In High HDL group, no significant associations were 
found between the TaqIB polymorphism and baseline lipid 
profile. 
I405V Polymorphism 
  The II genotype was more frequent in Low HDL group 
compared to High HDL group (54.7% vs 37.3%, p=0.02), 
while the IV genotype frequency was higher in High HDL 
group compared with Low HDL group (48.2% vs 31.3%, 
p=0.03).  
Effect of Atorvastatin on Lipid Profile in the Whole Cohort 
and Both Groups 
  Total cholesterol, LDL-C and TG levels were signifi-
cantly decreased after atorvastatin administration (-34.4%, -
41.2% and -28.5%, respectively; p<0.001 for each). The 
HDL-C slightly increased though not significantly 2.8% 
(p=0.46).  
  The changes in total cholesterol, HDL-C, LDL-C and TG 
levels were:-37.0% (p<0.001), +12.9% (p<0.001), -40.1% 
(p<0.001), -38.1% (p<0.001), respectively in the Low HDL 
group and -30.9% (p<0.001), -8.3% (p=0.001), -43.2% 
(p<0.001), -15.2% (p<0.001), respectively in the High HDL 
group.  
Effect of Atorvastatin Treatment According to Genotype of 
the Whole Cohort 
  The B1 carriers increased HDL-C levels by 4% after 
atorvastatin treatment, compared with B2 carriers, where a 
4% decrease was found (p=0.03). Also homozygotes for B1 
allele decreased TG levels in a lesser, though not significant, 
degree compared with B1B2 or B2B2 genotypes [20.6%, 
35.8% or 29.1%, respectively (all 3 decreases significant: 
p<0.001, p=0.40 for in-between comparison)]. 
Association of the I405V or TaqIB Variants with Effective-
ness of Atorvastatin in Low and High HDL Group 
  B2 carriers from Low HDL group had greater decrease of 
total cholesterol compared with B1 carriers (-120 (44) mg/dl 
vs -100(58) mg/dl, p=0.02), Table 3. Also, B2 carriers from 
the Low HDL group had greater decrease of TG compared 
with B1 carriers (-45% vs. -37%, p=0.02). 
  In the High HDL group, LDL-C showed greater decrease 
in subjects with II genotype compared with those with IV 
genotype [-108 mg/dl (-47.2%) vs -79 mg/dl (-37.1%), 
p=0.006].  
DISCUSSION 
  We evaluated whether the common CETP TaqIB or 
I405V gene polymorphism was associated with differentia-
tion of the plasma lipid profile and involvement of the 
atorvastatin effectiveness on lipid lowering. Our results show 
that TaqIB polymorphism modulated the effectiveness of 
atorvastatin reduction on lipid values, especially on HDL-C 
and TG (to a lesser degree). Also, in the Low HDL group the 
effectiveness of reduction of total cholesterol and TG varied 
according to TaqIB polymorphism. In the High HDL group 
the % reduction of LDL-C varied according to I405V poly-
morphism.  
  The gene frequencies for the TaqIB and I405V polymor-
phisms in our study cohort were similar to those reported in 
other Caucasian [3, 12, 13] and dyslipidaemic populations 
[14]. For example, the population in the Regression Growth 
Evaluation Statin Study (REGRESS) had similar TaqIB al-
lele frequencies with our population (B1: 59% vs 58.9% and 
B2: 41% vs 41.1%, respectively) [15]. In another study in-
volving Greek dyslipidaemic individuals, the V allele fre-
quency was 33% and in Greeks with coronary artery disease 
32% [8, 16], all similar to the present study (34.5%).  
Table 2.  Baseline Lipid Profile of the Study Cohort Based on TaqIB or I405V Alleles 
CETP TaqIB  CETP I405V 
   B1  B2  p  I  V  p 
Age (years)  59(20)  57(20)  0.43  57(20)  60(19)  0.09 
BMI (kg/m2)  27(4)  26(4)  0.91  27(4)  27(4)  0.82 
TC (mg/dl)  280(66)  294(68)  0.04  287(70)  285(65)  0.33 
TG (mg/dl)  165(115)  144(128)  0.39  163(126)  144(112)  0.11 
HDL-C (mg/dl)  42(19)  48(19)  0.02  43(20)  48(19)  0.04 
LDL-C (mg/dl)  190(61)  197(81)  0.41  190(77)  194(74)  0.26 
All continuous variables are shown as median and interquartile range. Mann-Whitney U statistic was used to compare the continuous variables among the three genotype groups. 
CETP: cholesteryl ester transfer protein, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total cholesterol, TG: 
triglycerides. B1: variant allele-carrying genotypes (B1B1, B1B2), B2: variant allele-carrying genotypes (B2B2, B1B2), I: variant allele-carrying genotypes (II, IV) , V : variant 
allele-carrying genotypes (VV, VI). For TC, HDL and LDL, to convert from mg/dl to mmol/l divide by 38.8. For TG, to convert from mg/dl to mmol/l divide by 88.6. 300    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Kolovou et al. 
  Concerning the baseline lipid profile, the VV and B2B2 
genotypes have been reported to present with higher HDL-C 
levels [2, 8]. Similarly, in the present study, the B2B2 geno-
types, as well as the B2 allele, were associated with higher 
HDL-C levels. The IV (rather than the VV) genotype and V 
allele was associated with higher HDL-C levels. However, 
no such association was found for the VV genotype which 
could be attributed to the low number of subjects with this 
genotype.  
  Despite the proven efficacy of statins as a primary and 
secondary prevention for cardiovascular disease, a signifi-
cant proportion of patients do not achieve LDL-C goals [17]. 
This could be due to the interindividual variability in the 
response to statin treatment [18]. In the REGRESS study, 
pravastatin reduced total cholesterol, LDL-C, and TG levels 
and increased HDL-C to a similar extent in all 3 TaqIB 
genotypes [15]. However, in animals study de Haan et al. 
[19] reported that atorvastatin increased HDL-C by reducing 
hepatic CETP expression in E3L.CETP mice (APOE*3-
Leiden mice crossbred with mice expressing human CETP). 
This fact supported the hypothesis that CETP gene polymor-
phisms could play an important role in the lipid lowering 
effectiveness of atorvastatin. Also, van Venrooij et al., who 
evaluated the cohort (n=217) from Diabetes Atorvastatin 
Lipid Intervention (DALI) study (frequency of B1 allele 
similar to our study 57.1%), reported that in carriers with the 
B1B1
 genotype, HDL-C levels increased, whereas in B2B2 
carriers, atorvastatin had no effect on HDL-C [20]. Poduri et 
al. [21] found association with reduced LDL-C lowering by 
atorvastatin and gene polymorphisms involved in lipid me-
tabolism (including CETP gene) in an Indian population. 
They compared the wild-allele homozygote genotype vs 
variant allele carrying heterozygote and homozygote geno-
types and found that variant allele-carrying genotype of 
TaqIB showed greater increase in HDL-C concentrations 
following atorvastatin therapy and variant allele carrying 
I405V showed lower reduction in total cholesterol levels. 
Contrary to our findings, patients involved in their study had 
coronary artery disease, were mostly men and had median 
total cholesterol of 204(35) mg/dl and HDL-C of 35(9) 
mg/dl, while subjects in our study were dyslipidaemic, 30% 
were women and had total cholesterol 286(69) mg/dl and 
HDL-C 44(20) mg/dl. Furthermore, Mohrschladt et al. did 
not find any differences between TaqIB and statin treatment 
[22]. In a previous study of ours, the TaqIB had no influence 
on response to treatment with simvastatin opposite to I405V 
polymorphism, where I allele carriers responded better [8]. 
In the present study, carriers of B1 allele increased HDL-C 
levels after atorvastatin therapy, while the carriers of B2 al-
leles decreased the HDL-C levels. One explanation is that 
carriers of the B2 allele had higher HDL-C levels at baseline 
[42(19) mg/dl vs 48(19) mg/dl, respectively]. In the Low 
HDL group the B2 carriers responded better to statin therapy 
(greater reduction of total cholesterol and TGs). Moreover, 
in the High HDL-C group the II genotype was associated 
with greater % reduction of LDL-C and B1B1 genotype with 
lower reduction of HDL-C after atorvastatin treatment. Pos-
sible explanation for this discrepancy may be that another 
statin was used (atorvastatin instead of simvastatin). Overall, 
subjects with low HDL-C levels at baseline seem to benefit 
to a greater extent than those with high HDL-C levels at 
baseline after atorvastatin treatment. The HDL-C level was 
significantly increased (+12.9%) and TGs were significantly 
Table 3.  Differences (in mg/dl) in Lipid Profile of the Whole Study Cohort According to I405V or TaqIB Alleles after Atorvastatin 
Treatment in Low and High HDL Groups 
Low HDL group 
CETP TaqIB  CETP I405V   
B1 B2  P  I  V  p 
TC -100(58)  -120(44)  0.02  -103(66)  -112(41) 0.38 
TG -50(103)  -118(157)  0.05  -61(150)  -82(140) 0.63 
HDL-C   5(10)  3(8)  0.22  4(9)  2(17)  0.25 
LDL-C   -55(85)  -79(89)  0.28  -52(94)  -85(52)  0.12 
High HDL group 
CETP TaqIB  CETP I405V   
B1 B2  p  I  V  P 
TC -89(52)  -89(59)  0.93  -90(58)  -88(52) 0.60 
TG -22(75)  -35(65)  0.59  -33(77)  -21(56) 0.56 
HDL-C -4(12)  -5(14) 0.25  -4(12)  -5(14)  0.42 
LDL-C -78(52)  -88(58) 0.89  -84(52)  -86(49)  0.58 
All continuous variables are shown as median and interquartile range. Mann-Whitney U statistic was used to compare the continuous variables among the two allele groups. CETP: 
cholesteryl ester transfer protein, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total cholesterol, TG: 
triglycerides, diff: Difference between value after and value before atorvastatin treatment. 
B1: variant allele-carrying genotypes (B1B1, B1B2), B2: variant allele-carrying genotypes (B2B2, B1B2), I: variant allele-carrying genotypes (II, IV) , V : variant allele-carrying 
genotypes (VV, VI). For TC, HDL and LDL, to convert from mg/dl to mmol/l divide by 38.8. For TG, to convert from mg/dl to mmol/l divide by 88.6. Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid  The Open Cardiovascular Medicine Journal, 2010, Volume 4    301 
decreased (-38%) in group with low HDL-C compared with -
8.3% and -15.2%, respectively in the group with high HDL-
C. The different response to hypolipidaemic drugs according 
the HDL-C baseline levels was suggested by our research 
group since 1995 [7, 23, 24]. At that time, this was only a 
clinical observation. However, the response to statin treat-
ment is not solely influenced by a single gene polymor-
phism. Furthermore, the pharmacogenetic studies on associa-
tion between genes and lipid lowering response to statins are 
limited [25]. Many factors could contribute to an individ-
ual’s response such as side effects, gender, age, body mass 
index, diet, environmental, CETP mass and activity (CETP 
genotypes may influence both by approximately 5% to 10%) 
[26], as well as gene-gene interaction. Gene assessment also 
has cost and time implications which are disadvantages in 
routine clinical practice. Nevertheless, these disadvantages 
may become less relevant as technology develops.  
CONCLUSIONS 
  The results favour the hypothesis that CETP polymor-
phisms modify the effect of statin treatment and may help to 
identify subjects who will benefit more from statin therapy. 
Thus, the prospective identification of subjects who have a 
diminished or increased response to statins, may improve the 
risk-to-benefit ratio of statin therapy. However, this is a 
small study. To clarify the genes contribution to the statin 
lipid lowering effect more studies involving higher number 
of individuals are required.  
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